Department of Medicine, Chicago Medical School, Rosalind Franklin University, Chicago, IL, USA.
J Cardiovasc Pharmacol. 2012 Feb;59(2):198-205. doi: 10.1097/FJC.0b013e31823a109f.
A few trials have investigated the efficacy of colesevelam in the reduction of glycemic and lipid outcomes. These meta-analysis pooled data from 8 such trials and found that colesevelam is associated with significant reductions in plasma fasting glucose, hemoglobin A1c, and low-density lipoprotein. Insignificant reductions in high-density lipoprotein and total cholesterol were also noted along with significant increase in triglycerides. This analysis concludes that colesevelam may be of particular benefit in managing type 2 diabetic patients with hyperlipidemia in whom low-density lipoprotein levels are of particular concern. Caution should be taken in patients who have hypertriglyceridemia or low high-density lipoprotein levels before starting therapy.
一些试验已经研究了考来烯胺在降低血糖和血脂方面的疗效。这些荟萃分析汇总了 8 项此类试验的数据，结果发现考来烯胺可显著降低空腹血糖、糖化血红蛋白和低密度脂蛋白。高密度脂蛋白和总胆固醇也有轻微降低，同时甘油三酯显著升高。该分析得出结论，考来烯胺对于治疗患有血脂异常的 2 型糖尿病患者可能特别有益，尤其是对于那些特别关注低密度脂蛋白水平的患者。在开始治疗前，对于患有高甘油三酯血症或低高密度脂蛋白血症的患者应谨慎。
